Five cancer researchers receive 2021 New Discoveries Young Investigator Awards from BCAN

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Five researchers have received the 2021 New Discoveries Young Investigator Awards from the Bladder Cancer Advocacy Network. 

This is the first year BCAN has presented five awards. 

  • The 2021 New Discoveries Young Investigator Awards went to Brendan Guercio, a Hematology/Oncology fellow at Memorial Sloan Kettering Cancer Center, and Eugene Pietzak, assistant attending surgeon (urologic oncology) at Memorial Sloan Kettering Cancer Center. Guercio’s project title is “Associations of Patient Diet and Benefit from Immunotherapy in Urothelial Carcinoma” and Pietzak’s is titled “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.”

Each Young Investigator Award provides a $50,000 grant that supports one year of early career bladder cancer research. Since 2009, BCAN has awarded more than $5.5 million to promising scientists and research investigators across the country and these awards demonstrate that the important work to improve the understanding of bladder cancer and its impact on patients and families continues.

  • The two 2021 Palm Beach New Discoveries Young Investigator awardees are Filipe De Carvalho, urologic oncology fellow at Brigham and Women’s Hospital, and Benjamin Miron, medical oncology fellow at Fox Chase Cancer Center.  The title of Carvalho’s awarded project is “Clonal Architecture and Tumor Microenvironment of Cisplatin Resistant Localized Muscle Invasive Bladder Cancer” and Miron’s is “Relationship of Circulating Tumor DNA in Patients with Muscle Invasive Bladder Cancer to Pathologic Staging and Disease Prognosis.”
  • The 2021 New Discoveries Young Investigator Award for Patient Centered Research was awarded to Svetlana Avulova, urologic oncology fellow at Mayo Clinic. Avulova’s project is titled “Sexual Function in Women Undergoing Radical Cystectomy.”

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login